written by reader Mannkind MNKD

By Anonymous Questions, February 26, 2015

Could the good Dr. comment on Mannkind, now that itโ€™s Affrezza insulin inhaler is now on the market. Iโ€™m of the opinion that this could be a game changer, particularly for those who just canโ€™t stand the thought of daily needles.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

Share your thoughts...

2 Comment threads
0 Thread replies
Most reacted comment
Hottest comment thread
2 Comment authors
MRTVindia white Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Afrezza is a rapid acting insulin–ie, for meal times for diabetics. Most people also use a basal (long-acting insulin) as well, which is only available as an injection. Granted, this would cut down to one-two injections per day, versus at every meal. So, the daily needle has not gone away, although the development of an inhaled long acting insulin might be a possibility. Also, this would be limited to those patients who do not have asthma, COPD, etc.


Nobody wants it, niche product at absolute best. The needles are so small now days in pens that there is nothing to be afraid of. Hate MNKD, Alfred will go down the tubes on this one UNLESS……… he can license the delivery technology, that is the true key. Not Insulin.